Impact of Inhaled Insulin on the Insulin Market

The first inhaled formulation of rapid-acting insulin, Pfizer's Exubera, has just reached the market. Several other inhaled insulins are now in late-stage development. This technology is likely to impact the insulin market signifi cantly, adding new players and potentially changing medical practice by lowering current barriers to initiation of insulin therapy. Get the Answers You Need to Shape Your Strategy The long-term success of inhaled insulins will depend on third-party payer reimbursement policies, long-term safety data, and perceived convenience for the patient. What will provide emerging agents with a decisive competitive advantage? Including Exubera, which emerging inhaled insulin appears to have an edge in patient convenience? Third-party payers are increasingly establishing policies that seek to contain the rising costs of health care. How have reimbursement policy makers responded to the availability of inhaled insulin? Aside from cost, what are the perceived disadvantages of inhaled insulins compared with injectable insulins? Exubera will reap some benefit from being the first agent on the market, but the novelty of the technology will require Pfizer to expend signifi cant resources to educate physicians and patients on its benefits. How important is Exubera to Pfizer? Will Exubera be able to maintain its market advantage as competitors enter a market prepared for them by Pfizer's awareness campaign? Which inhaled insulin systems now in development will pose the greatest challenge to Exubera? Please note: the PDF e-mail from publisher version of this report is for a global site license.

Additional Information

Companies:
Alkermes
Amylin
Aradigm
Biocon
Coremed
Eli Lilly
Emisphere
ooooooo
Generex Biotechnology
Kos Pharmaceuticals
MannKind
Nektar
Novo Nordisk
Pfi zer
QDose
Sanofi -Aventis